דספרל 0.5 גרם Ізраїль - іврит - Ministry of Health

דספרל 0.5 גרם

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.

אקסג'ייד 125 מג Ізраїль - іврит - Ministry of Health

אקסג'ייד 125 מג

novartis israel ltd - deferasirox - טבליות ניתנות לפיזור - deferasirox 125 mg - deferasirox - deferasirox - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over).exjade is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration (lic) >5 mg fe/g dry weight (dw) following mri and serum ferritin >800 nanogram/ml).

אקסג'ייד 500 מג Ізраїль - іврит - Ministry of Health

אקסג'ייד 500 מג

novartis israel ltd - deferasirox - טבליות ניתנות לפיזור - deferasirox 500 mg - deferasirox - deferasirox - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over).exjade is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration (lic) >5 mg fe/g dry weight (dw) following mri and serum ferritin >800 nanogram/ml).

אקסג'ייד 250 מג Ізраїль - іврит - Ministry of Health

אקסג'ייד 250 מג

novartis israel ltd - deferasirox - טבליות ניתנות לפיזור - deferasirox 250 mg - deferasirox - deferasirox - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over).exjade is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration (lic) >5 mg fe/g dry weight (dw) following mri and serum ferritin >800 nanogram/ml).

פרינג'קט Ізраїль - іврит - Ministry of Health

פרינג'קט

cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial - ferinject is indicated for treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. the diagnosis must be based on laboratory tests.

דספרל 0.5 גרם Ізраїль - іврит - Ministry of Health

דספרל 0.5 גרם

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine

פרינג'קט Ізраїль - іврит - Ministry of Health

פרינג'קט

cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial

פרינג'קט Ізраїль - іврит - Ministry of Health

פרינג'קט

cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial

פרינג'קט Ізраїль - іврит - Ministry of Health

פרינג'קט

cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial

קימריה Ізраїль - іврит - Ministry of Health

קימריה

novartis israel ltd - tisagenlecleucel - tisagenlecleucel